The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Romanova I.V.

Moscow Scientic and Practical Center of Dermatvenerology and Cosmetology. Moscow, Russia, 119071

Kisina V.I.

I.M. Sechenov Moscow Medical Academy

Khayrullina G.A.

Central Research Institute for Epidemiology, Moscow, Russian, 111123

Frigo N.V.

Moscow Sientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071

Zhukova O.V.

I.M. Sechenov Moscow Medical Academy

Gushchin A.E.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare, Moscow, Russia

The prevalence and type of mutations of in dermatovenereological patients from the Moscow region for 2014‒2018

Authors:

Romanova I.V., Kisina V.I., Khayrullina G.A., Frigo N.V., Zhukova O.V., Gushchin A.E.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2020;19(1): 7‑12

DOI: 10.17116/klinderma2020190117

Read: 1364 times

Download PDF (RU)
Contact the author
Table of contents

THE PREVALENCE AND TYPE OF MUTATIONS OF IN DERMATOVENEREOLOGICAL PATIENTS FROM THE MOSCOW REGION FOR 2014‒2018
THE PREVALENCE AND TYPE OF MUTATIONS OF IN DERMATOVENEREOLOGICAL PATIENTS FROM THE MOSCOW REGION FOR 2014‒2018

To cite this article:

Romanova IV, Kisina VI, Khayrullina GA, Frigo NV, Zhukova OV, Gushchin AE. The prevalence and type of mutations of in dermatovenereological patients from the Moscow region for 2014‒2018. Russian Journal of Clinical Dermatology and Venereology. 2020;19(1):7‑12. (In Russ.)
https://doi.org/10.17116/klinderma2020190117

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Relevance and purpose. The rapid development of antibiotic resistance of Mycoplasma genitalium is an important global problem of the last decade. The purpose of this research was to study the frequency and type of mutations of M.genitalium in dynamics in dermatovenereological patients from the Moscow region. Material and methods. Retrospectively examined urogenital samples of M.genitalium-positive patients for the presence of mutations causing resistance to macrolides and fluoroquinolones. Results. Analyzed 645 samples of patients with M.genitalium-infection for 2014—2018. Macrolide-resistant M.genitalium isolates were detected in 7.4% of the samples (6.02—15.69% for 2014—2018). The most common mutations were in positions A2058 (37.5%) and A2059 (50%), respectively. Fluoroquinolone-resistant strains were detected in 9.8% of cases (7.14—13.73% for 2014—2018), while mutations G248 (38.1%) and G259 (49.2%) were more common. Conclusions. The prevalence of mutant strains of M.genitalium associated with resistance to macrolides and fluoroquinolones in the Moscow region was 7.4% and 9.8%, respectively. For 2014—2018 there is an increase in the number of mutations causing resistance to macrolides by 2.6 times (from 6.02% to 15.69%), causing resistance to fluoroquinolones — by 1.9 times (from 7.14% to 13.73%).

Keywords:

Mgenitalium-infection
resistance to macrolides and fluoroquinolones
mutant strains

Authors:

Romanova I.V.

Moscow Scientic and Practical Center of Dermatvenerology and Cosmetology. Moscow, Russia, 119071

Kisina V.I.

I.M. Sechenov Moscow Medical Academy

Khayrullina G.A.

Central Research Institute for Epidemiology, Moscow, Russian, 111123

Frigo N.V.

Moscow Sientific and Practical Center of Dermatovenereology and Cosmetology, Moscow, Russia, 119071

Zhukova O.V.

I.M. Sechenov Moscow Medical Academy

Gushchin A.E.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare, Moscow, Russia

Close metadata

References:

  1. Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2016;30:1650-1656. https://doi.org/10.1111/jdv.13849
  2. Horner PJ, Martin DH. Mycoplasma genitalium Infection in Men. J Infect Dis. 2017 Jul 15;216(Suppl 2):S396-S405. https://doi.org/10.1093/infdis/jix145
  3. Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis. 2015;61:418-426. https://doi.org/10.1093/cid/civ312
  4. Gnanadurai R, Fifer H. Mycoplasma genitalium: A Review. Microbiology. 2019 Jul 22. https://doi.org/10.1099/mic.0.000830
  5. Manhart LE, Kay N. Mycoplasma genitalium: is it a sexually transmitted pathogen? Curr Infect Dis Rep. 2010;12:306-313. https://doi.org/10.1136/bmj.k4573
  6. Ma L, Taylor S, Jensen JS, et al. Short tandem repeat sequences in the Mycoplasma genitalium genome and their use in a multilocus genotyping system. BMC Microbiol. 2008;8:130. https://doi.org/10.1186/1471-2180-8-130
  7. Cohen CR, Nosek M, Meier A, et al. Mycoplasma genitalium infection and persistence in a cohort of female sex workers in Nairobi, Kenya. Sex Transm Dis. 2007;34:274-279. https://doi.org/10.1097/01.olq.0000237860.61298.54
  8. Oakeshott P, Aghaizu A, Hay P, et al. Is Mycoplasma genitalium in women the «New Chlamydia»? A community-based prospective cohort study. Clin Infect Dis. 2010;51:1160-1166. https://doi.org/10.1086/656739
  9. Baumann L, Cina M, Egli-Gany D, et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis. Sex Transm Infect. 2018;94:255-262. https://doi.org/10.1101/180422
  10. Kapiga SH, Sam NE, Mlay J, et al. The epidemiology of HIV-1 infection in northern Tanzania: results from a community-based study. AIDS Care. 2006;18:379-387. https://doi.org/10.1080/09540120500465012
  11. Mavedzenge SN, Van Der Pol B, Weiss HA, et al. The association between Mycoplasma genitalium and HIV-1 acquisition in African women. AIDS. 2012;26:617-624. https://doi.org/10.1097/qad.0b013e32834ff690
  12. Perez G, Skurnick JH, Denny TN, et al. Herpes simplex type II and Mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis. 1998;3:5-11. https://doi.org/10.1016/s1201-9712(98)90088-1
  13. McGowin CL, Anderson-Smits C. Mycoplasma genitalium: an emerging cause of sexually transmitted disease in women. PLoS Pathog. 2011 May; 7(5):e1001324. https://doi.org/10.1371/journal.ppat.1001324
  14. 2018 BASHH UK national guidance for the management of infection with Mycoplasma genitalium. BASHH UK National Guideline. 2018. http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium#management
  15. Unemo M, Salado-Rasmussen K, Hansen M, et al. Clinical and analytical evaluation of the new Aptima Mycoplasma genitalium assay, with data on M.genitalium prevalence and antimicrobial resistance in M.genitalium in Denmark, Norway and Sweden in 2016. Clin Microbiol Infect. 2018;24:533-539. https://doi.org/10.1016/j.cmi.2017.09.006
  16. Jensen JS, Bradshaw CS, Tabrizi SN, et al. Azithromycin treatment failure in Mycoplasma genitalium — positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47:1546-1553. https://doi.org/10.1086/593188
  17. Asenjo A, Kusters JG, Severs TT, Alós J-I. Mycoplasma genitalium in Spain: prevalence of genital infection and frequency of resistance to macrolides. Enfermedades Infecciosas y Microbiología Clínica. 2018;36:169-171. https://doi.org/10.1016/j.eimce.2017.01.039
  18. Pitt R, Fifer H, Woodford N, Alexander S. Detection of markers predictive of macrolide and fluoroquinolone resistance in Mycoplasma genitalium from patients attending sexual health services in England. Sex Transm Infect. 2018;94:9-13. https://doi.org/10.1136/sextrans-2017-053164
  19. Dionne-Odom J, Geisler WM, et al. High prevalence of multidrug-resistant Mycoplasma genitalium in human immunodeficiency virus-infected men who have sex with men in Alabama. Clin Infect Dis. 2018;66:796-798. https://doi.org/10.1093/cid/cix853
  20. Horner P, Ingle SM, Garrett F, et al. Which azithromycin regimen should be used for treating Mycoplasma genitalium? A meta-analysis. Sex Transm Infect 2018;94:14-20. https://doi.org/10.1136/sextrans-2016-053060
  21. Read TRH, Fairley CK, Murray GL, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium Infections: a prospective evaluation. Clin Infect Dis. 2019;68:554-560. https://doi.org/10.1136/sextrans-2017-053264.105
  22. Australian Sexual Health Alliance 2018; Mycoplasma genitalium — Australian STI management guidelines for primay care. http://www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium#management
  23. Couldwell DL, Tagg KA, Jeoffreys NJ, Gilbert GL. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS. 2013;24:822-828. https://doi.org/10.1177/0956462413502008
  24. Richter SS, Patel JB. Mechanisms of Resistance to Antibacterial Agents. In: Manual of Clinical Microbiology, 11th Edition. American Society of Microbiology; 2015:1212-1245. https://doi.org/10.1128/9781555817381.ch69
  25. Deguchi T, Ito S, Yasuda M, et al. Surveillance of the prevalence of macrolide and/or fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Japan. J Infect Chemother. 2018;24:861-867. https://doi.org/10.1016/j.jiac.2018.08.009
  26. Hamasuna R, Le PT, Kutsuna S, et al. Mutations in parC and gyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains. PLoS One 2018. https://doi.org/10.1371/journal.pone.0198355
  27. Kikuchi M, Ito S, Yasuda M, et al. Remarkable increase in fluoroquinolone-resistant Mycoplasma genitalium in Japan. J Antimicrob Chemother. 2014;69:2376-2382. https://doi.org/10.1093/jac/dku164
  28. Ito S, Shimada Y, Yamaguchi Y, et al. Selection of Mycoplasma genitalium strains harbouring macrolide resistance-associated 23S rRNA mutations by treatment with a single 1 G dose of azithromycin. Sex Transm Infect. 2011;87:412-414. https://doi.org/10.1136/sextrans-2011-050035
  29. Takahashi S, Hamasuna R, Yasuda M, et al. Clinical efficacy of sitafloxacin 100 mg twice daily for 7 days for patients with non-gonococcal urethritis. J Infect Chemother. 2013;19:941-945. https://doi.org/10.1016/s0924-8579(13)70392-3
  30. Deguchi T, Ito S, Yasuda M, et al. Emergence of Mycoplasma genitalium with clinically significant fluoroquinolone resistance conferred by amino acid changes both in gyrA and parC in Japan. J Infect Chemother. 2017;23:648-650. https://doi.org/10.1016/j.jiac.2017.03.008
  31. Pond MJ, Nori AV, Witney AA, et al. High prevalence of antibiotic-resistant Mycoplasma genitalium in nongonococcal urethritis: the need for routine testing and the inadequacy of current treatment options. Clin Infect Dis. 2014;58:631-637. https://doi.org/10.1093/cid/cit752
  32. Braam JF, van Dommelen L, Henquet CJM, et al. Multidrug-Resistant Mycoplasma genitalium infections in Europe. Eur J Clin Microbiol Infect Dis. 2017;36:1565-1567. https://doi.org/10.1007/s10096-017-2969-9
  33. Peyriere H, Makinson A, Marchandin H, Reynes J. Doxycycline in the management of sexually transmitted infections. Journal of Antimicrobial Chemotherapy. 2018;73:553-563. https://doi.org/10.1093/jac/dkx420
  34. Blanchard A, Bébéar C. The evolution of Mycoplasma genitalium. Ann N Y Acad Sci. 2011;1230:E61-E64. https://doi.org/10.1111/j.1749-6632.2011.06418.x
  35. Shipitsyna E, Rumyantseva T, Golparian D, et al. Prevalence of macrolide and fluoroquinolone resistance-mediating mutations in Mycoplasma genitalium in five cities in Russia and Estonia. PLoS One. 2017 Apr 13;12(4): e0175763. https://doi.org/10.1371/journal.pone.0175763
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.